Defence Therapeutics Inc.
DTC
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -2.99M | -8.53M | -9.72M | -10.03M | -10.03M |
| Total Depreciation and Amortization | 77.90K | 65.20K | 61.70K | 26.80K | 10.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 499.30K | 6.43M | 6.37M | 6.26M | 6.31M |
| Change in Net Operating Assets | 912.70K | 1.02M | 1.15M | 384.90K | -286.70K |
| Cash from Operations | -1.50M | -1.02M | -2.15M | -3.36M | -4.00M |
| Capital Expenditure | -146.10K | -146.10K | -150.90K | -167.00K | -8.50K |
| Sale of Property, Plant, and Equipment | 13.30K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -132.80K | -146.10K | -150.90K | -167.00K | -8.50K |
| Total Debt Issued | 65.00K | 65.00K | 50.00K | 0.00 | 0.00 |
| Total Debt Repaid | -172.90K | -43.40K | -30.30K | -16.30K | -14.70K |
| Issuance of Common Stock | 2.27M | 1.47M | 1.47M | 3.63M | 6.93M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -146.00K | -124.60K | -124.60K | -246.30K | -340.80K |
| Cash from Financing | 1.47M | 1.01M | 1.01M | 2.51M | 4.87M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -159.20K | -158.70K | -1.29M | -1.02M | 868.70K |